301166 优宁维
交易中 12-23 10:38:00
资讯
新帖
简况
优宁维(301166.SZ)股东泰礼投资及其一致行动人完成减持1.36%股份
智通财经网 · 11-25
优宁维(301166.SZ)股东泰礼投资及其一致行动人完成减持1.36%股份
优宁维11月19日现4笔大宗交易 成交金额800.22万元
新浪证券-红岸工作室 · 11-19
优宁维11月19日现4笔大宗交易 成交金额800.22万元
优宁维(301166)2024年三季报简析:净利润减65.05%,三费占比上升明显
证券之星 · 10-30
优宁维(301166)2024年三季报简析:净利润减65.05%,三费占比上升明显
图解优宁维三季报:第三季度单季净利润同比减117.64%
证券之星 · 10-28
图解优宁维三季报:第三季度单季净利润同比减117.64%
优宁维(301166)9月30日股东户数1.2万户,较上期增加2.32%
证券之星 · 10-28
优宁维(301166)9月30日股东户数1.2万户,较上期增加2.32%
优宁维(301166.SZ)发布前三季度业绩,净利润1407.91万元,下降65.05%
智通财经 · 10-28
优宁维(301166.SZ)发布前三季度业绩,净利润1407.91万元,下降65.05%
优宁维:9月13日召开业绩说明会,投资者参与
证券之星 · 09-14
优宁维:9月13日召开业绩说明会,投资者参与
优宁维(301166)9月2日主力资金净买入189.15万元
证券之星 · 09-03
优宁维(301166)9月2日主力资金净买入189.15万元
优宁维(301166)2024年中报简析:净利润减56.27%
证券之星 · 08-31
优宁维(301166)2024年中报简析:净利润减56.27%
优宁维(301166.SZ)发布上半年业绩,净利润1509.51万元,下降56.27%
智通财经 · 08-29
优宁维(301166.SZ)发布上半年业绩,净利润1509.51万元,下降56.27%
优宁维(301166)8月28日主力资金净卖出420.38万元
证券之星 · 08-29
优宁维(301166)8月28日主力资金净卖出420.38万元
优宁维(301166)8月27日主力资金净买入80.48万元
证券之星 · 08-28
优宁维(301166)8月27日主力资金净买入80.48万元
优宁维(301166)8月21日主力资金净卖出136.74万元
证券之星 · 08-22
优宁维(301166)8月21日主力资金净卖出136.74万元
千金藤素概念盘中跳水,优宁维跌3.73%
自选股智能写手 · 08-19
千金藤素概念盘中跳水,优宁维跌3.73%
优宁维(301166)8月16日主力资金净卖出396.91万元
证券之星 · 08-19
优宁维(301166)8月16日主力资金净卖出396.91万元
A股午后猴痘概念持续拉升,海辰药业、亚太药业2连板,透景生命、普利制药、合富中国涨停,博晖创新、优宁维、之江生物、迈克生物等多股涨超5%。
美港电讯 · 08-16
A股午后猴痘概念持续拉升,海辰药业、亚太药业2连板,透景生命、普利制药、合富中国涨停,博晖创新、优宁维、之江生物、迈克生物等多股涨超5%。
优宁维(301166)8月15日主力资金净买入125.75万元
证券之星 · 08-16
优宁维(301166)8月15日主力资金净买入125.75万元
【猴痘概念板块活跃,海辰药业、亚太药业涨停 公司回应来了】金十数据8月15日讯,猴痘概念板块活跃,海辰药业、亚太药业涨停,博晖创新、优宁维、万泰生物等涨超4%。
美港电讯 · 08-15
【猴痘概念板块活跃,海辰药业、亚太药业涨停 公司回应来了】金十数据8月15日讯,猴痘概念板块活跃,海辰药业、亚太药业涨停,博晖创新、优宁维、万泰生物等涨超4%。
【优宁维:公司猴痘体外检测产品主要用于科研 在国内外没有获批】金十数据8月15日讯,从优宁维证券部获悉,公司猴痘体外检测产品主要是科研用途,用量不大,目前在国内外尚未获批。
美港电讯 · 08-15
【优宁维:公司猴痘体外检测产品主要用于科研 在国内外没有获批】金十数据8月15日讯,从优宁维证券部获悉,公司猴痘体外检测产品主要是科研用途,用量不大,目前在国内外尚未获批。
A股猴痘概念股开盘大涨,海辰药业、亚太药业涨停,西点药业、博晖创新涨超10%,凯普生物、优宁维、达安基因等均大幅高开。
美港电讯 · 08-15
A股猴痘概念股开盘大涨,海辰药业、亚太药业涨停,西点药业、博晖创新涨超10%,凯普生物、优宁维、达安基因等均大幅高开。
加载更多
公司概况
公司名称:
上海优宁维生物科技股份有限公司
所属行业:
批发业
上市日期:
2021-12-28
主营业务:
上海优宁维生物科技股份有限公司是一家面向高等院校、科研院所、医院和生物医药企业等,提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务的科学服务商。公司主要产品及服务有生命科学试剂、生命科学仪器及耗材、综合技术服务。目前公司提供生命科学产品SKU约870万种,覆盖基因、蛋白、细胞、组织及动物等不同水平的研究对象,涵盖生命科学基础研究、医学基础研究、体外诊断研究、药物研发、细胞治疗研究等领域,是国内生命科学产品种类及规格最全面的供应商之一。
发行价格:
86.06
{"stockData":{"symbol":"301166","market":"SZ","secType":"STK","nameCN":"优宁维","latestPrice":29.87,"timestamp":1734921480000,"preClose":30.54,"halted":0,"volume":391145,"delay":0,"floatShares":41268900,"shares":86666700,"eps":0.1629,"marketStatus":"交易中","marketStatusCode":2,"change":-0.67,"latestTime":"12-23 10:38:00","open":30.54,"high":30.58,"low":29.8,"amount":11738600,"amplitude":0.0255,"askPrice":29.87,"askSize":4,"bidPrice":29.85,"bidSize":8,"shortable":0,"etf":0,"ttmEps":0.1629,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1734924600000},"adr":0,"adjPreClose":30.54,"symbolType":"stock","openAndCloseTimeList":[[1734917400000,1734924600000],[1734930000000,1734937200000]],"highLimit":33.59,"lowLimit":27.49,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":86666668,"pbRate":1.27,"roa":"--","roe":"--","epsLYR":0.47,"committee":0.350993,"marketValue":2589000000,"floatMarketCap":1233000000,"peRate":183.364026,"changeRate":-0.0219,"turnoverRate":0.0095,"status":1},"requestUrl":"/m/hq/s/301166","defaultTab":"news","newsList":[{"id":"2486086391","title":"优宁维(301166.SZ)股东泰礼投资及其一致行动人完成减持1.36%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2486086391","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486086391?lang=zh_cn&edition=full","pubTime":"2024-11-25 20:51","pubTimestamp":1732539116,"startTime":"0","endTime":"0","summary":"智通财经APP讯,优宁维(301166.SZ)公告,公司股东上海创业接力泰礼创业投资中心(有限合伙)(简称“泰礼投资”)及其一致行动人上海泰礼创业投资管理有限公司-上海含泰创业投资合伙企业(有限合伙)(简称“含泰投资”)合计减持公司股份117.27万股,占公司总股本比例1.36%,本次减持计划已期限届满。更多港股重磅资讯,下载智通财经app更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1215643.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["301166","BK0250"],"gpt_icon":0},{"id":"2484997371","title":"优宁维11月19日现4笔大宗交易 成交金额800.22万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484997371","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484997371?lang=zh_cn&edition=full","pubTime":"2024-11-19 17:01","pubTimestamp":1732006860,"startTime":"0","endTime":"0","summary":" 11月19日,优宁维收涨3.25%,收盘价为31.09元,发生4笔大宗交易,合计成交量31.28万股,成交金额800.22万元。 进一步统计,近3个月内该股累计发生4笔大宗交易,合计成交金额为800.22万元。该股近5个交易日累计下跌4.19%,主力资金合计净流出847.46万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-11-19/doc-incwqvpq2894987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301166","BK0250"],"gpt_icon":0},{"id":"2479261210","title":"优宁维(301166)2024年三季报简析:净利润减65.05%,三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2479261210","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479261210?lang=zh_cn&edition=full","pubTime":"2024-10-30 06:35","pubTimestamp":1730241348,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期优宁维发布2024年三季报。截至本报告期末,公司营业总收入8.28亿元,同比下降6.6%,归母净利润1407.91万元,同比下降65.05%。按单季度数据看,第三季度营业总收入2.75亿元,同比下降11.64%,第三季度归母净利润-101.6万元,同比下降117.64%。本报告期优宁维三费占比上升明显,财务费用、销售费用和管理费用总和占总营收同比增幅达43.95%。去年的净利率为3.29%,算上全部成本后,公司产品或服务的附加值不高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000007428.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166"],"gpt_icon":0},{"id":"2478711881","title":"图解优宁维三季报:第三季度单季净利润同比减117.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478711881","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478711881?lang=zh_cn&edition=full","pubTime":"2024-10-28 17:18","pubTimestamp":1730107087,"startTime":"0","endTime":"0","summary":"证券之星消息,优宁维2024年三季报显示,公司主营收入8.28亿元,同比下降6.6%;归母净利润1407.91万元,同比下降65.05%;扣非净利润-401.69万元,同比下降120.64%;其中2024年第三季度,公司单季度主营收入2.75亿元,同比下降11.64%;单季度归母净利润-101.6万元,同比下降117.64%;单季度扣非净利润-519.29万元,同比下降1803.45%;负债率9.43%,投资收益1007.69万元,财务费用-404.09万元,毛利率18.54%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102800023346.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166"],"gpt_icon":0},{"id":"2478179792","title":"优宁维(301166)9月30日股东户数1.2万户,较上期增加2.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478179792","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478179792?lang=zh_cn&edition=full","pubTime":"2024-10-28 17:08","pubTimestamp":1730106530,"startTime":"0","endTime":"0","summary":"证券之星消息,近日优宁维披露,截至2024年9月30日公司股东户数为1.2万户,较6月30日增加272.0户,增幅为2.32%。在生物制品行业个股中,优宁维股东户数低于行业平均水平,截至9月30日,生物制品行业平均股东户数为3.36万户。从股价来看,2024年6月30日至2024年9月30日,优宁维区间涨幅为18.48%,在此期间股东户数增加272.0户,增幅为2.32%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102800022829.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2478270178","title":"优宁维(301166.SZ)发布前三季度业绩,净利润1407.91万元,下降65.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478270178","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478270178?lang=zh_cn&edition=full","pubTime":"2024-10-28 16:19","pubTimestamp":1730103590,"startTime":"0","endTime":"0","summary":"智通财经APP讯,优宁维(301166.SZ)发布2024年三季度报告,该公司前三季度营业收入为8.28亿元,同比减少6.60%。归属于上市公司股东的净利润为1407.91万元,同比减少65.05%。归属于上市公司股东的扣除非经常性损益的净亏损为401.69万元。基本每股收益为0.16元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1201164.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301166"],"gpt_icon":0},{"id":"2467203385","title":"优宁维:9月13日召开业绩说明会,投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2467203385","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467203385?lang=zh_cn&edition=full","pubTime":"2024-09-14 06:40","pubTimestamp":1726267236,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年9月13日优宁维发布公告称公司于2024年9月13日召开业绩说明会。与此同时,公司加大精细化管理,加强费用成本管控,推行降本增效,努力实现投入与当期利润之间的平衡。公司客户中涉及国内小部分保健食品领域企业。公司围绕抗体极致战略,持续加大对自主产品的研发投入力度,公司自主产品持续丰富。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024091400005514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"gpt_icon":0},{"id":"2464189764","title":"优宁维(301166)9月2日主力资金净买入189.15万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2464189764","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464189764?lang=zh_cn&edition=full","pubTime":"2024-09-03 09:12","pubTimestamp":1725325941,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年9月2日收盘,优宁维报收于27.22元,上涨3.07%,换手率6.52%,成交量2.69万手,成交额7406.43万元。近5日资金流向一览见下表:优宁维融资融券信息显示,融资方面,当日融资买入771.34万元,融资偿还385.34万元,融资净买入386.0万元。优宁维主营业务:公司面向高等院校、科研院所、医院和生物医药企业等,提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090300008061.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"gpt_icon":0},{"id":"2463371668","title":"优宁维(301166)2024年中报简析:净利润减56.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2463371668","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463371668?lang=zh_cn&edition=full","pubTime":"2024-08-31 06:38","pubTimestamp":1725057537,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期优宁维发布2024年中报。根据财报显示,优宁维净利润减56.27%。截至本报告期末,公司营业总收入5.53亿元,同比下降3.87%,归母净利润1509.51万元,同比下降56.27%。按单季度数据看,第二季度营业总收入2.81亿元,同比下降6.57%,第二季度归母净利润989.26万元,同比下降40.4%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024083100009980.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166"],"gpt_icon":0},{"id":"2463896642","title":"优宁维(301166.SZ)发布上半年业绩,净利润1509.51万元,下降56.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2463896642","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463896642?lang=zh_cn&edition=full","pubTime":"2024-08-29 17:18","pubTimestamp":1724923082,"startTime":"0","endTime":"0","summary":"智通财经APP讯,优宁维(301166.SZ)发布2024年半年度报告,该公司营业收入为5.53亿元,同比减少3.87%。归属于上市公司股东的净利润为1509.51万元,同比减少56.27%。归属于上市公司股东的扣除非经常性损益的净利润为117.61万元,同比减少93.86%。基本每股收益为0.17元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1174801.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301166"],"gpt_icon":0},{"id":"2463423692","title":"优宁维(301166)8月28日主力资金净卖出420.38万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2463423692","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463423692?lang=zh_cn&edition=full","pubTime":"2024-08-29 09:21","pubTimestamp":1724894519,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月28日收盘,优宁维报收于25.93元,下跌2.81%,换手率3.39%,成交量1.4万手,成交额3631.01万元。近5日资金流向一览见下表:优宁维融资融券信息显示,融资方面,当日融资买入262.75万元,融资偿还438.84万元,融资净偿还176.1万元。优宁维主营业务:公司面向高等院校、科研院所、医院和生物医药企业等,提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082900010537.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2462173507","title":"优宁维(301166)8月27日主力资金净买入80.48万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2462173507","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462173507?lang=zh_cn&edition=full","pubTime":"2024-08-28 09:14","pubTimestamp":1724807659,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月27日收盘,优宁维报收于26.68元,上涨2.18%,换手率3.77%,成交量1.56万手,成交额4168.71万元。近5日资金流向一览见下表:优宁维融资融券信息显示,融资方面,当日融资买入335.76万元,融资偿还587.1万元,融资净偿还251.34万元。优宁维主营业务:公司面向高等院校、科研院所、医院和生物医药企业等,提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082800011229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"gpt_icon":0},{"id":"2461527382","title":"优宁维(301166)8月21日主力资金净卖出136.74万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2461527382","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461527382?lang=zh_cn&edition=full","pubTime":"2024-08-22 09:21","pubTimestamp":1724289713,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月21日收盘,优宁维报收于27.77元,下跌4.57%,换手率6.62%,成交量2.73万手,成交额7588.65万元。近5日资金流向一览见下表:优宁维融资融券信息显示,融资方面,当日融资买入658.28万元,融资偿还615.75万元,融资净买入42.53万元。优宁维主营业务:公司面向高等院校、科研院所、医院和生物医药企业等,提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082200008671.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2460264724","title":"千金藤素概念盘中跳水,优宁维跌3.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460264724","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460264724?lang=zh_cn&edition=full","pubTime":"2024-08-19 09:46","pubTimestamp":1724032004,"startTime":"0","endTime":"0","summary":"08月19日,千金藤素概念盘中跳水,截至09点46分,千金藤素概念整体指数下跌0.59%,报784.260点。从个股上来看,该概念的成分股中,优宁维跌3.73%,方盛制药、皓元医药、海王生物跌幅居前。从资金上来看,截止发稿,千金藤素概念主力净流入为-747.63万,其中皓元医药受到资金热捧,主力净流入169.32万;拉长时间线来看,该板块近20日主力资金净流入-4.79亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081909464496826a72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081909464496826a72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688131","301166","BK0250","BK0216"],"gpt_icon":0},{"id":"2460726726","title":"优宁维(301166)8月16日主力资金净卖出396.91万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2460726726","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460726726?lang=zh_cn&edition=full","pubTime":"2024-08-19 09:11","pubTimestamp":1724029888,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月16日收盘,优宁维报收于31.35元,上涨7.99%,换手率14.66%,成交量6.05万手,成交额1.85亿元。近5日资金流向一览见下表:优宁维融资融券信息显示,融资方面,当日融资买入1993.11万元,融资偿还1501.71万元,融资净买入491.4万元,连续3日净买入累计721.92万元。优宁维主营业务:公司面向高等院校、科研院所、医院和生物医药企业等,提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081900002321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"gpt_icon":0},{"id":"2459522952","title":"A股午后猴痘概念持续拉升,海辰药业、亚太药业2连板,透景生命、普利制药、合富中国涨停,博晖创新、优宁维、之江生物、迈克生物等多股涨超5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2459522952","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459522952?lang=zh_cn&edition=full","pubTime":"2024-08-16 13:44","pubTimestamp":1723787075,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["399300","301166","159982","002370","BK0239","BK0132","300642","BK0012","688317","300584","BK0048","BK0028","300630","BK0042","BK0251","603122","300463","BK0046","BK0250","300318"],"gpt_icon":0},{"id":"2459235465","title":"优宁维(301166)8月15日主力资金净买入125.75万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2459235465","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459235465?lang=zh_cn&edition=full","pubTime":"2024-08-16 09:12","pubTimestamp":1723770730,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月15日收盘,优宁维报收于29.03元,上涨5.76%,换手率7.55%,成交量3.11万手,成交额9085.98万元。近5日资金流向一览见下表:优宁维融资融券信息显示,融资方面,当日融资买入700.44万元,融资偿还628.69万元,融资净买入71.75万元。优宁维主营业务:公司面向高等院校、科研院所、医院和生物医药企业等,提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081600014752.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2459417039","title":"【猴痘概念板块活跃,海辰药业、亚太药业涨停 公司回应来了】金十数据8月15日讯,猴痘概念板块活跃,海辰药业、亚太药业涨停,博晖创新、优宁维、万泰生物等涨超4%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2459417039","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459417039?lang=zh_cn&edition=full","pubTime":"2024-08-15 16:57","pubTimestamp":1723712244,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["09633","300318","002370","LU1981816686.USD","301166","BK0239","BK0028","603392","BK0132","BK0251","BK0048","BK1200","BK0250","300584","BK1589"],"gpt_icon":0},{"id":"2459949339","title":"【优宁维:公司猴痘体外检测产品主要用于科研 在国内外没有获批】金十数据8月15日讯,从优宁维证券部获悉,公司猴痘体外检测产品主要是科研用途,用量不大,目前在国内外尚未获批。","url":"https://stock-news.laohu8.com/highlight/detail?id=2459949339","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459949339?lang=zh_cn&edition=full","pubTime":"2024-08-15 12:30","pubTimestamp":1723696209,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0250","301166"],"gpt_icon":0},{"id":"2459045717","title":"A股猴痘概念股开盘大涨,海辰药业、亚太药业涨停,西点药业、博晖创新涨超10%,凯普生物、优宁维、达安基因等均大幅高开。","url":"https://stock-news.laohu8.com/highlight/detail?id=2459045717","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459045717?lang=zh_cn&edition=full","pubTime":"2024-08-15 09:28","pubTimestamp":1723685304,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["002030","BK0239","BK0251","BK0122","BK0132","002370","BK0250","BK0168","300318","BK0048","301130","BK0188","159982","300639","399300","BK0042","300584","301166","BK0159","BK0028","BK0046"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-12-28","address":"上海市杨浦区控江路1690号1505室","stockEarnings":[{"period":"1week","weight":-0.0261},{"period":"1month","weight":-0.048},{"period":"3month","weight":0.2014},{"period":"6month","weight":0.0792},{"period":"1year","weight":-0.1947},{"period":"ytd","weight":-0.1924}],"companyName":"上海优宁维生物科技股份有限公司","boardCode":"AI0051","perCapita":"3437股","boardName":"批发业","registeredCapital":"8666万元","compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":0},{"period":"3month","weight":0.2307},{"period":"6month","weight":0.1234},{"period":"1year","weight":0.154},{"period":"ytd","weight":0.1321}],"survey":" 上海优宁维生物科技股份有限公司是一家面向高等院校、科研院所、医院和生物医药企业等,提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务的科学服务商。公司主要产品及服务有生命科学试剂、生命科学仪器及耗材、综合技术服务。目前公司提供生命科学产品SKU约870万种,覆盖基因、蛋白、细胞、组织及动物等不同水平的研究对象,涵盖生命科学基础研究、医学基础研究、体外诊断研究、药物研发、细胞治疗研究等领域,是国内生命科学产品种类及规格最全面的供应商之一。","serverTime":1734921485764,"listedPrice":86.06,"stockholders":"12006人(较上一季度增加2.32%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"优宁维(301166)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供优宁维(301166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"优宁维,301166,优宁维股票,优宁维股票老虎,优宁维股票老虎国际,优宁维行情,优宁维股票行情,优宁维股价,优宁维股市,优宁维股票价格,优宁维股票交易,优宁维股票购买,优宁维股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"优宁维(301166)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供优宁维(301166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}